TEZSPIRE (AstraZeneca Pty Ltd)
Product name
TEZSPIRE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
173 (255 working days)
Active ingredients
tezepelumab
Registration type
EOI
Indication
Chronic rhinosinusitis with nasal polyps (CRSwNP)
TEZSPIRE is indicated as an add-on maintenance treatment in patients aged 18 years and older with severe CRSwNP with inadequate response to intranasal corticosteroids and a history of surgery and/or systemic corticosteroid use.